This is a Phase 1 Study of Eribulin Mesylate in Pediatric Patients With Recurrent or Refractory Solid Tumors (Excluding CNS), Including Lymphomas

Trial Profile

This is a Phase 1 Study of Eribulin Mesylate in Pediatric Patients With Recurrent or Refractory Solid Tumors (Excluding CNS), Including Lymphomas

Recruiting
Phase of Trial: Phase I

Latest Information Update: 19 Nov 2016

At a glance

  • Drugs Eribulin (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms BOLD 113
  • Sponsors Eisai Inc
  • Most Recent Events

    • 31 Oct 2016 Planned number of patients changed from 20 to 23.
    • 15 Sep 2016 Planned primary completion date changed from 1 Jul 2017 to 1 Nov 2016.
    • 07 Jun 2016 Results (n=23) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top